These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19951881

  • 21. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V, Fuchs M, GHSG.
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [Abstract] [Full Text] [Related]

  • 22. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 23. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.
    Acta Haematol; 2016 Nov 10; 135(3):156-61. PubMed ID: 26588173
    [Abstract] [Full Text] [Related]

  • 24. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
    Wongso D, Fuchs M, Plütschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer G, Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A.
    J Clin Oncol; 2013 Aug 01; 31(22):2819-24. PubMed ID: 23796987
    [Abstract] [Full Text] [Related]

  • 25. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
    J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
    [Abstract] [Full Text] [Related]

  • 26. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.
    J Clin Oncol; 2009 Sep 20; 27(27):4548-54. PubMed ID: 19704068
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of advanced Hodgkin lymphoma].
    Kreissl S, Borchmann P.
    Dtsch Med Wochenschr; 2013 Jun 20; 138(23):1212-4. PubMed ID: 23720173
    [No Abstract] [Full Text] [Related]

  • 28. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP.
    Semin Oncol; 1990 Feb 20; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [Abstract] [Full Text] [Related]

  • 29. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
    Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, von Tresckow B.
    J Clin Oncol; 2015 Aug 01; 33(22):2430-6. PubMed ID: 26101245
    [Abstract] [Full Text] [Related]

  • 30. Which Hodgkin's patients in the Unites States should be treated with BEACOPP?
    Cheson BD.
    Curr Hematol Malig Rep; 2014 Sep 01; 9(3):222-6. PubMed ID: 24879421
    [Abstract] [Full Text] [Related]

  • 31. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
    Avivi I, Hardak E, Shaham B, Igla M, Rowe JM, Dann EJ.
    Ann Hematol; 2012 Feb 01; 91(2):215-21. PubMed ID: 21603918
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
    Elbl L, Vasova I, Kral Z, Tomaskova I, Smardova L, Wagnerova B, Jedlicka F, Vorlicek J.
    J Chemother; 2006 Apr 01; 18(2):199-208. PubMed ID: 16736890
    [Abstract] [Full Text] [Related]

  • 33. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7555-64. PubMed ID: 16234521
    [Abstract] [Full Text] [Related]

  • 34. Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
    Morabito F, Hohaus S, Mammi C, Marcheselli L, Gentile M, Merli F, Montanini A, Stelitano C, La Sala A, Scalone R, Voso MT, Luminari S, Iannitto E, Gobbi P, Federico M.
    Leuk Lymphoma; 2012 Mar 20; 53(3):406-10. PubMed ID: 21916526
    [Abstract] [Full Text] [Related]

  • 35. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 36. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group.
    N Engl J Med; 2003 Jun 12; 348(24):2386-95. PubMed ID: 12802024
    [Abstract] [Full Text] [Related]

  • 37. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 38. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F.
    Br J Haematol; 2004 Jun 01; 125(5):584-9. PubMed ID: 15147373
    [Abstract] [Full Text] [Related]

  • 39. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
    Boltežar L, Pintarić K, Jezeršek Novaković B.
    J Assist Reprod Genet; 2016 Mar 01; 33(3):325-333. PubMed ID: 26678493
    [Abstract] [Full Text] [Related]

  • 40. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
    Bujan L, Walschaerts M, Brugnon F, Daudin M, Berthaut I, Auger J, Saias J, Szerman E, Moinard N, Rives N, Hennebicq S.
    Fertil Steril; 2014 Sep 01; 102(3):667-674.e3. PubMed ID: 25044088
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.